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‘Systems Technologies’ are increasingly potent drivers of
biological research. Molecular Systems Biology will be illus-
trating this evolution with a new Reviews Series highlighting
key technologies in systems medicine, genome-scale, compu-
tational, quantitative and synthetic biology. The series is
launched with a review from the Snyder group on reading
human omes (Soon et al, 2013) and a companion review on
writing genomes from Harvard’s Wyss Institute (Esvelt and
Wang, 2013).
Past achievements, future milestones
Exponential improvement in reading and writing technologies
(Carr and Church, 2009) (1.5-fold/year since 1960s, 6-fold per
year since 2005) created a series of breakthroughs: The ﬁrst
genome read wasMS2 in 1976 (phiX in 1977); ﬁrst writtenwas
hepatitis C virus in 2000 (Blight et al, 2000) (polio in 2002).
The ﬁrst bacterial genome read was Helicobacter in 1994
(Haemophilus in 1995). The ﬁrst genome transplanted from
in vitro DNA into radically foreign cytoplasm was Synechocys-
tis into Bacillus in 2005 (then Mycoplasma mycoides into
similar cytoplasm in 2007). Signiﬁcantly, so far, no vertebrate
genome has been fully read, due to repetitive regions, and no
new organism function has been achieved by genome-scale
writing. We expect to see breakthroughs on both fronts
in 2013.
Utility beyond research feeding more
research
The ﬁrst widely used genetic engineering vector was pBR322,
constructed and sequenced 1977-1978, parts of which are still
present in modern vectors. This enabled dissection of
previously recalcitrant biological systems via pure compo-
nents and swiftly lead to commercial production of a stream of
human proteins, including insulin, interferons, epo and
therapeutic antibodies. Proteins still constitute the fastest
growingcategoryof new therapeutics.Comparative genomics,
metabolic engineering and systems biology (Schirmer et al,
2010) have resulted in factories already at production-scale for
chemicals, fuels and pharmaceuticals.
What next for reading omes?
Some say that due to other costs, the plummeting human
genome price will stop at $1000, but the million-fold cost
improvement changes not only how we read our once-in-a-
lifetime inherited genomes, but also how we can measure our
day-to-day immunome response to our microbiome, cancer
transcriptome and allergome. Portable nanopore devices with
minimalsamplehandlingand100-kbpreadscouldenablereal-
time environmental air and food monitoring. Nanotags seem
ready to greatly improve raw sequencing accuracy (Kumar
et al, 2012) and detection of modiﬁed bases (Korlach and
Turner, 2012). Another technology with a potentially huge
impact on systems biology will be ﬂuorescent in situ sequen-
cing, enabling studies of not just single cells, but subcellular
and multicellular features, and reveal tumor and develop-
mental cell-to-cell heterogeneity. Combined with super-
resolution ﬂuorescent microscopy, in situ measures will reveal
the 3D structure of genomes, epigenomes and cells (Beliveau
et al, 2012). This allows us to go beyond ENCODE (Bernstein
et al, 2012) and ‘Organs-on-chips’, which pragmatically
employ cancer-like cells and primary cells from poorly
documented human sources, to well-deﬁned open-access
personal genome cells (Ball et al, 2012), engineered human
cells and even human plus bacterial cells in synthetic gut
ecosystems (Kim et al, 2012).
From reading to diagnostics
Will we need $100000 to interpret our $1000 genome?
Certainly not. Automation of data analysis workﬂows and
minimization of false-positive diagnostic outcomes already
deliver full genome interpretation for $400 per genome
(a fraction of the $4000 raw sequence). Interpretation will
expand from simple Mendelian models to multigenic, multi-
environmental component systems models. This transition
will beneﬁt from shareable integrated ‘precision medicine’
data sets on individuals (not averages). Despite the increase in
actionable gene tests from a few in 1990–2700 today, a vocal
few insist that personalgenomics is not worth it. Yes; DNA like
many other diagnostics may not reveal anything new, but you
don’t knowuntil you look. We should not restrict gene tests by
family history, as many afﬂicted are the ﬁrst in their family.
Notably as we learn to better control environmental factors,
the genetic component (heritability) of a disease can increase
(unbounded by previous association studies or twin studies
conducted before the reduction in environmental compo-
nents). Ironically, the push for larger cohorts in the name of
statistical power, results in confounding via lumping of
disparate types. Focusing instead on phenotypic extremes
(positive and negative) can result in clearer diagnostics,
preventatives and therapies applicable across the whole
spectrum. Furthermore, systems approaches focused on
causality rather than correlation seem quite promising, even
with cohorts as small as N¼1. Examples of going from
genome-wide analyses to treatment are accumulating (e.g.,
Nic Volker, the Beery twins, Mike Snyder, John Lauerman).
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epigenomic grand challenges
The ﬁrst question is why? Why genome-wide rather than a few
genes? Genome engineering enables non-standard amino
acids, safety isolation and multi-virus resistance (Isaacs et al,
2011). Making one genome at a time at high cost (albeit
decreasing) misses a key advantage not available to other
engineeringﬁelds,whichistheabilitytousesystemknowledge
and clever selections on billions of genomes. Construction of
such billions beneﬁtsfromsynthesis ofrawoligos on chipsand
usingcombinatorialmultiplexautomatedgenomeengineering.
For more difﬁcult organisms, we need extra guidance for
genomic and epigenomic reprogramming via Zn-Fingers,
TALEs or CRISPR (Mali et al, 2012). We will see growing use
of sequencing to quantitate phenotypes of large libraries (of
codons, cis-regulatory signals, etc) and library-by-library
measures (antibodies versus antigens, RNA versus protein,
etc). The ability to synthesize and deliver complex mixtures
(Kimetal,2011)ofmRNAs,miRNAs,siRNAsandgRNAsputus
on the verge of a transition matrix among all normal and
pathological epigenomic states, and therapies (Figure 1).
From writing to therapeutics
Just as proteins are ‘smarter’ than small molecules, cells are
smarter still. Genetic therapy has transitioned from random
viral payload integration in the 1990s to precise targeting
today.AZn-ﬁnger-nucleasetargetingCCR5DNAisapromising
treatmentforAIDSnowinphase2trials.Alsoremarkableisthe
extensionoftheconceptofenhancingdrugsanddevices—such
as cognitive enhancers—to the notion of enhancing gene
therapies that will ‘cure’ people of their common genotype
using a minor variant—rather than the older goal of ﬁxing rare
genetic diseases using the common variant.
In conclusion, reading and writing technologies are now
extending across a broad range of physical and multiplexing
scales. Combining multiplexing at the sequence level with
parallelized sample processingprovide biologists with system-
wide functional testing approaching with sufﬁcient power to
match the large-scale hypothesis generation that typically
results from ome data.
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